ZA200501137B - Pyrrolidone derivatives as MAOB inhibitors - Google Patents

Pyrrolidone derivatives as MAOB inhibitors

Info

Publication number
ZA200501137B
ZA200501137B ZA200501137A ZA200501137A ZA200501137B ZA 200501137 B ZA200501137 B ZA 200501137B ZA 200501137 A ZA200501137 A ZA 200501137A ZA 200501137 A ZA200501137 A ZA 200501137A ZA 200501137 B ZA200501137 B ZA 200501137B
Authority
ZA
South Africa
Prior art keywords
pyrrolidone derivatives
maob inhibitors
maob
inhibitors
pyrrolidone
Prior art date
Application number
ZA200501137A
Other languages
English (en)
Inventor
Iding Hans
Krummenacher Daniela
Thomas Andrew William
Wostl Wolfgang
Jolidon Synese
Sarmiento Rosa Maria Rodriguez
Wirz Beat
Wyler Rene
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200501137B publication Critical patent/ZA200501137B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA200501137A 2002-09-20 2005-02-08 Pyrrolidone derivatives as MAOB inhibitors ZA200501137B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02021319 2002-09-20

Publications (1)

Publication Number Publication Date
ZA200501137B true ZA200501137B (en) 2006-12-27

Family

ID=32010924

Family Applications (3)

Application Number Title Priority Date Filing Date
ZA200501137A ZA200501137B (en) 2002-09-20 2005-02-08 Pyrrolidone derivatives as MAOB inhibitors
ZA200501311A ZA200501311B (en) 2002-09-20 2005-02-14 Pyrrolidone derivatives as MAOB inhibitors
ZA200501557A ZA200501557B (en) 2002-09-20 2005-02-22 4-Pyrrolidino-phenyl-benzyl ether derivatives.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ZA200501311A ZA200501311B (en) 2002-09-20 2005-02-14 Pyrrolidone derivatives as MAOB inhibitors
ZA200501557A ZA200501557B (en) 2002-09-20 2005-02-22 4-Pyrrolidino-phenyl-benzyl ether derivatives.

Country Status (32)

Country Link
US (4) US7235581B2 (fr)
EP (3) EP1542971A1 (fr)
JP (3) JP4335142B2 (fr)
KR (3) KR100676015B1 (fr)
CN (3) CN100503562C (fr)
AR (3) AR041299A1 (fr)
AT (2) ATE472530T1 (fr)
AU (3) AU2003270213B8 (fr)
BR (4) BR0314299A (fr)
CA (3) CA2498335A1 (fr)
CY (1) CY1110745T1 (fr)
DE (2) DE60333202D1 (fr)
DK (1) DK1542970T3 (fr)
ES (2) ES2338646T3 (fr)
GT (3) GT200300204A (fr)
HK (3) HK1083498A1 (fr)
HR (3) HRP20050262A2 (fr)
JO (2) JO2605B1 (fr)
MX (3) MXPA05002880A (fr)
MY (3) MY134480A (fr)
NO (3) NO330012B1 (fr)
NZ (3) NZ538049A (fr)
PA (3) PA8583001A1 (fr)
PE (3) PE20050077A1 (fr)
PL (3) PL216030B1 (fr)
PT (1) PT1542970E (fr)
RU (3) RU2336267C2 (fr)
SI (1) SI1542970T1 (fr)
TW (3) TWI286132B (fr)
UY (3) UY27991A1 (fr)
WO (3) WO2004026826A1 (fr)
ZA (3) ZA200501137B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8583001A1 (es) * 2002-09-20 2004-04-23 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil eter como inhibidores de mao-b
GB0314373D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
KR100845366B1 (ko) * 2004-08-02 2008-07-09 에프. 호프만-라 로슈 아게 모노아민 산화효소 ｂ 억제제로서 벤질옥시 유도체
NZ552649A (en) * 2004-08-02 2010-05-28 Hoffmann La Roche Benzyloxy derivatives as monoamine oxidase-B (MAOB) inhibitors
RU2007129642A (ru) 2005-02-25 2009-03-27 Ф.Хоффманн-Ля Рош Аг (Ch) Таблетки с улучшенным распределением лекарственного вещества
ATE415388T1 (de) * 2005-03-15 2008-12-15 Hoffmann La Roche Verfahren zur herstellung von enantiomerenreinen 4-pyrrolidinophenyl- benzyletherderivaten
US7501528B2 (en) * 2005-03-15 2009-03-10 Hoffmann-La Roche Inc. Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives
TW200728258A (en) * 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
JP5139307B2 (ja) * 2005-10-10 2013-02-06 グラクソ グループ リミテッド ナトリウムチャネルモジュレーターとしてのプロリンアミド誘導体
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
US8372380B2 (en) * 2007-03-30 2013-02-12 The Regents Of The University Of California In vivo imaging of sulfotransferases
KR101220182B1 (ko) * 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
CZ304053B6 (cs) * 2011-08-22 2013-09-04 Farmak, A. S. Zpusob prípravy 2-[4-[(methylamino)karbonyl]-1-H-pyrazol-1-yl]adenosinu monohydrátu
KR102018284B1 (ko) * 2013-02-28 2019-09-05 삼성디스플레이 주식회사 박막 트랜지스터 어레이 기판 및 이를 포함하는 유기 발광 표시 장치
CN105143190B (zh) 2013-03-14 2017-08-18 达特神经科学(开曼)有限公司 作为mao抑制剂的被取代的萘啶和喹啉化合物
CZ305213B6 (cs) 2013-04-29 2015-06-10 Farmak, A. S. Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy
CN105705487A (zh) * 2013-10-29 2016-06-22 豪夫迈·罗氏有限公司 可用于治疗阿尔茨海默病的吡咯烷酮衍生物的晶形及其制备
WO2016102967A1 (fr) 2014-12-23 2016-06-30 Convergence Pharmaceuticals Limited Procédé de préparation de dérivés d'alpha-carboxamide de pyrrolidine
JP2018509400A (ja) * 2015-03-27 2018-04-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ セムブラギリンを含む医薬製剤
WO2019065794A1 (fr) 2017-09-27 2019-04-04 国立大学法人鹿児島大学 Médicament analgésique utilisant un médicament antagoniste du récepteur pac1
SG10202112966SA (en) 2017-10-05 2021-12-30 Biogen Inc Process for preparing αlpha-carboxamide pyrrolidine derivatives
CN108299272B (zh) * 2018-01-31 2019-10-18 福州大学 一种合成1-氯-2,2,2-三氟亚乙基取代咯酮化合物的方法
SG11202008543RA (en) 2018-03-08 2020-10-29 Sunshine Lake Pharma Co Ltd Pyrrolidineamide derivatives and uses thereof
WO2020175134A1 (fr) 2019-02-27 2020-09-03 国立大学法人鹿児島大学 Agent antiprurigineux utilisant un antagoniste du récepteur pac1
JP7049637B1 (ja) 2020-05-08 2022-04-07 国立大学法人 鹿児島大学 Ｐａｃ１受容体拮抗薬を用いた抗うつ・抗不安薬
CN112851561A (zh) * 2021-01-29 2021-05-28 南京艾美斐生物医药科技有限公司 一种nr6a1蛋白受体抑制剂及其制备和应用
WO2022268520A1 (fr) 2021-06-21 2022-12-29 Bayer Aktiengesellschaft Utilisation de pyrrolidinones substituées ou de leurs sels pour augmenter la tolérance au stress des plantes

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348393A (en) * 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
FR2500831A1 (fr) 1981-02-27 1982-09-03 Delalande Sa Nouvelles n-aryl-oxazolidinones et -pyrrolidinones
DE69025418T2 (de) 1989-04-19 1996-11-14 Otsuka Pharma Co Ltd Phenylcarbonsäurederivate mit einem Heterocyclus
US5679715A (en) 1995-06-07 1997-10-21 Harris; Richard Y. Method for treating multiple sclerosis
CA2244253C (fr) 1996-03-15 2002-11-12 Somerset Pharmaceuticals, Inc. Methode de prevention et de traitement de la neuropathie peripherique par administration de selegiline
US5683404A (en) * 1996-06-05 1997-11-04 Metagen, Llc Clamp and method for its use
DE19841895A1 (de) 1998-09-11 2000-03-23 Degussa Neues Verfahren zur Herstellung von 3-Amino-2-oxo-pyrrolidinen, neue Zwischenprodukte und deren Verwendung
AU4181000A (en) * 1999-04-02 2000-10-23 Du Pont Pharmaceuticals Company Novel lactam inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase
AU1359801A (en) 1999-11-05 2001-06-06 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
WO2001058388A1 (fr) * 2000-02-10 2001-08-16 Potencia Medical Ag Traitement d'incontinence d'urine a base d'energie radioelectrique
AU2001232586A1 (en) * 2000-02-14 2001-07-09 Potencia Medical Ag Penile prosthesis
PA8583001A1 (es) * 2002-09-20 2004-04-23 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil eter como inhibidores de mao-b
US20040267291A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with non-mechanical attachment mechanism
US20040267292A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with transverse attachment mechanism

Also Published As

Publication number Publication date
PL376019A1 (en) 2005-12-12
UY27991A1 (es) 2004-03-31
CN100400509C (zh) 2008-07-09
PT1542970E (pt) 2010-07-19
ZA200501311B (en) 2006-10-25
HK1083499A1 (en) 2006-07-07
HRP20050263A2 (en) 2006-12-31
PL376021A1 (en) 2005-12-12
PA8583601A1 (es) 2004-09-16
JP4335142B2 (ja) 2009-09-30
RU2323209C2 (ru) 2008-04-27
TWI337604B (en) 2011-02-21
TW200408624A (en) 2004-06-01
CA2496756C (fr) 2012-01-10
HRP20050261A2 (en) 2006-05-31
PE20050078A1 (es) 2005-02-28
JP2006503833A (ja) 2006-02-02
RU2005111974A (ru) 2006-01-20
PE20050079A1 (es) 2005-03-01
RU2336267C2 (ru) 2008-10-20
GT200300204A (es) 2004-04-29
AU2003270213B8 (en) 2009-03-05
HRP20050263B1 (hr) 2013-09-30
CN1681777A (zh) 2005-10-12
JP2006510596A (ja) 2006-03-30
GT200300206A (es) 2004-04-29
MY133332A (en) 2007-11-30
ES2338646T3 (es) 2010-05-11
KR100676015B1 (ko) 2007-01-30
MXPA05002880A (es) 2005-05-27
ATE459601T1 (de) 2010-03-15
JO2605B1 (en) 2011-11-01
KR20050057466A (ko) 2005-06-16
JO2604B1 (en) 2011-11-01
US7235581B2 (en) 2007-06-26
JP2006503834A (ja) 2006-02-02
NZ538046A (en) 2007-08-31
AU2003273901A1 (en) 2004-04-08
KR20050057456A (ko) 2005-06-16
CA2498785C (fr) 2011-07-26
HK1083498A1 (en) 2006-07-07
US20040116707A1 (en) 2004-06-17
US7122562B2 (en) 2006-10-17
KR20050057450A (ko) 2005-06-16
EP1542969A1 (fr) 2005-06-22
NO20050652L (no) 2005-03-08
UY27993A1 (es) 2004-03-31
CN100383118C (zh) 2008-04-23
DE60331559D1 (de) 2010-04-15
AR041298A1 (es) 2005-05-11
HK1084383A1 (en) 2006-07-28
UY27990A1 (es) 2004-03-31
CA2498335A1 (fr) 2004-04-01
WO2004026827A1 (fr) 2004-04-01
KR100676014B1 (ko) 2007-01-30
ES2344557T3 (es) 2010-08-31
DE60333202D1 (de) 2010-08-12
DK1542970T3 (da) 2010-08-02
CA2498785A1 (fr) 2004-04-01
JP4335140B2 (ja) 2009-09-30
SI1542970T1 (sl) 2010-08-31
US7151111B2 (en) 2006-12-19
RU2005111968A (ru) 2006-11-10
CA2496756A1 (fr) 2004-04-01
BR0314299A (pt) 2005-12-13
BRPI0314631B1 (pt) 2018-04-17
EP1542971A1 (fr) 2005-06-22
AU2003270213B2 (en) 2009-02-12
TWI331994B (en) 2010-10-21
PA8583501A1 (es) 2004-04-23
WO2004026825A1 (fr) 2004-04-01
NO20050701L (no) 2005-03-02
HRP20050262A2 (en) 2006-06-30
AU2003273901B2 (en) 2008-07-10
BR0314631A (pt) 2005-08-02
NZ538048A (en) 2007-05-31
ZA200501557B (en) 2005-09-08
CN100503562C (zh) 2009-06-24
NZ538049A (en) 2007-05-31
US20060122235A1 (en) 2006-06-08
CN1681778A (zh) 2005-10-12
NO329754B1 (no) 2010-12-13
EP1542969B1 (fr) 2010-03-03
EP1542970A1 (fr) 2005-06-22
US7037935B2 (en) 2006-05-02
TWI286132B (en) 2007-09-01
AU2003270213A1 (en) 2004-04-08
MY135696A (en) 2008-06-30
CY1110745T1 (el) 2015-06-10
AU2003267381B2 (en) 2009-08-27
NO330012B1 (no) 2011-02-07
US20040106650A1 (en) 2004-06-03
AR041299A1 (es) 2005-05-11
ATE472530T1 (de) 2010-07-15
AU2003267381A1 (en) 2004-04-08
JP4335141B2 (ja) 2009-09-30
RU2005111969A (ru) 2006-01-20
AR041297A1 (es) 2005-05-11
MXPA05002878A (es) 2005-05-27
KR100681586B1 (ko) 2007-02-09
WO2004026826A1 (fr) 2004-04-01
US20040097578A1 (en) 2004-05-20
PL376018A1 (en) 2005-12-12
MXPA05002881A (es) 2005-05-27
PL216030B1 (pl) 2014-02-28
MY134480A (en) 2007-12-31
PA8583001A1 (es) 2004-04-23
CN1681779A (zh) 2005-10-12
PE20050077A1 (es) 2005-03-01
TW200410935A (en) 2004-07-01
TW200413350A (en) 2004-08-01
RU2336268C2 (ru) 2008-10-20
GT200300205A (es) 2004-04-29
NO20050665L (no) 2005-04-18
BR0314314A (pt) 2005-07-26
EP1542970B1 (fr) 2010-06-30

Similar Documents

Publication Publication Date Title
HK1083499A1 (en) Pyrrolidone derivatives as maob inhibitors
EG25482A (en) Inhibitors
IL173616A0 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
AU2003201850A1 (en) N-alkylsulfonyl-substituted amide derivatives
AU2003300832A8 (en) Nf-kappab inhibitors
EP1489088A4 (fr) Nouveau derive d'alpha-amino-n-(diaminophosphinyl)lactame
GB0315870D0 (en) Heterocyclic derivatives
IL172257A0 (en) Substituted pyrrole derivatives and their use as hmg-co inhibitors
EP1532133A4 (fr) Inhibiteurs de nf-:b
EP1570847A4 (fr) Inhibiteurs de phosphodiesterase 10a
HK1108432A1 (en) Benzyloxy derivatives as maob inhibitors
AU2003224941A8 (en) Nf-kappab inhibitors
GB2403474B (en) Amide derivatives
AU2003235889A8 (en) Amide derivatives
AU2003232362A8 (en) 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
GB2388841B (en) Polymerisable heterocyclic acetylenes
GB0226609D0 (en) Heterocyclic derivatives
HRP20050156A2 (en) Pyrrolidine derivatives as tryptase inhibitors
GB0311957D0 (en) Heterocyclic derivatives
IL169094A0 (en) 1-n-phenylamino-1h-imidazole derivatives as aromatase inhibitors
GB0208094D0 (en) Inhibitors
GB0226149D0 (en) Inhibitors
GB0224102D0 (en) Inhibitors
GB0217330D0 (en) Inhibitors
GB0207491D0 (en) Inhibitors